Pentwater Capital Management’s PureTech Health PRTC Stock Holding History

Pentwater Capital Management’s Portfolio PRTC Stock Details PRTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-70,000	Closed	-$1.04M	–	115
2026 Q1	$1.04M	Hold	70,000	–	–	0.01%	78
2025 Q4	$1.16M	Sell	70,000 -5,000	-7%	-$85.8K	0.01%	69
2025 Q3	$1.39M	Buy	75,000 +25,000	+50%	+$439K	0.01%	87
2025 Q2	$863K	Buy	50,000 +16,440	+49%	+$289K	0.01%	84
2025 Q1	$664K	Buy	33,560 +9,449	+39%	+$173K	0.01%	96
2024 Q4	$445K	Sell	24,111 -889	-4%	-$18.6K	﹤0.01%	84
2024 Q3	$515K	Buy	25,000 +8,807	+54%	+$192K	0.01%	86
2024 Q2	$405K	Sell	16,193 -807	-5%	-$22.6K	0.01%	88
2024 Q1	$485K	Buy	17,000 +6,756	+66%	+$173K	0.01%	92
2023 Q4	$289K	Buy	+10,244	New	+$209K	﹤0.01%	104

Pentwater Capital Management's PRTC Position: Q2 2026 in Review

Pentwater Capital Management sold out of PureTech Health (PRTC) in Q2 2026, closing a stake of 70,000 shares — an estimated $1.04M sold.

Pentwater Capital Management first reported a position in PRTC in Q4 2023 and held it in 10 quarters. The position peaked at $1.39M in Q3 2025. 0 funds tracked by Wall St. Rank hold PRTC as of Q2 2026.

Pentwater Capital Management reported no remaining PureTech Health position as of Q2 2026 after selling out during the quarter.
Pentwater Capital Management sold 70,000 PureTech Health shares in Q2 2026, an estimated $1.04M.
Pentwater Capital Management first reported a position in PureTech Health in Q4 2023 and held it in 10 quarters.
Pentwater Capital Management's PureTech Health position peaked at $1.39M in Q3 2025.
0 funds tracked by Wall St. Rank held PureTech Health as of Q2 2026.

Based on Pentwater Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.